Phase 2 Breast Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women who are postmenopausal at the start of the study — this includes women aged 50 or older who have not had a period for more than 12 months, or women under 50 who have had their menopause brought on by medical treatment such as ovarian suppression
• Women who have been diagnosed with early-stage breast cancer (stage I, II, or III) and received chemotherapy before or after surgery within the past 12 months
• Women with no signs of active or returning breast cancer, and no other serious ongoing illnesses
• Women whose physical fitness falls within a specific range, defined by being able to walk between 400 and 480 metres in 6 minutes at the start of the study (a level considered "pre-frail")
• People whose blood test results meet certain minimum levels for platelets, white blood cells, neutrophils, and haemoglobin (confirm specific values with trial site)
• People whose liver function tests and kidney function are within acceptable ranges as measured by blood tests (confirm specific values with trial site)
• People who are able to understand the study information and are willing to sign a written consent form

Who may not be able to join:

• People who have received cancer-directed chemotherapy, biological therapy, or immunotherapy within the 30 days before starting the study — though some specific treatments such as trastuzumab, pertuzumab, pembrolizumab, tamoxifen, and aromatase inhibitors may be exceptions
• People who have had surgery or radiation therapy within the 30 days before starting the study, with the possible exception of minor outpatient procedures such as a biopsy
• People currently taking certain medications that are not permitted in this trial — some medications may require a temporary pause rather than full stopping (confirm with trial site)
• People taking herbal or natural supplements that may have senolytic properties — such as curcumin, kava kava, or St. John's Wort — who are unwilling or unable to stop taking them for 2 days before and during the study treatment doses (CBD, vitamins, probiotics, and fish oil appear to be exceptions)
• People who have taken certain specific compounds in the past year, including fisetin, quercetin, luteolin, dasatinib, imatinib, other tyrosine kinase inhibitors, piperlongumine, or navitoclax
• People who are on blood-thinning medications at therapeutic (treatment-level) doses, such as warfarin, heparin, or similar drugs
• People who have difficulty taking oral medications — for example, those who cannot swallow pills, have absorption problems, are experiencing ongoing nausea or vomiting, or have a history of Crohn's disease, gastric bypass or reduction surgery, or coeliac disease
• People currently taking part in another research study aimed at improving physical function, reducing frailty, building muscle strength, reducing fatigue, or improving cognitive function
• People with any other condition that, in the study doctor's judgement, would make participation unsafe

Important: Always verify eligibility with the trial site directly before applying.